Status:
COMPLETED
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
Lead Sponsor:
Pfizer
Conditions:
Invasive Pneumococcal Disease
Eligibility:
All Genders
Up to 5 years
Brief Summary
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
- Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.
Exclusion
Key Trial Info
Start Date :
May 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
408 Patients enrolled
Trial Details
Trial ID
NCT00227188
Start Date
May 1 2003
End Date
December 1 2005
Last Update
November 29 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bilbao, Spain, 48903